Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer

Ye,Hua; Sun,Changqing; Ren,Pengfei; Dai,Liping; Peng,Bo; Wang,Kaijuan; Qian,Wei; Zhang,Jianying

doi:10.3892/ol.2012.1062

Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer

Authors:
- Hua Ye
- Changqing Sun
- Pengfei Ren
- Liping Dai
- Bo Peng
- Kaijuan Wang
- Wei Qian
- Jianying Zhang
View Affiliations

Affiliations: Department of Epidemiology and Henan Key Laboratory of Tumor Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China, Department of Biological Sciences, the University of Texas at El Paso, El Paso, TX 79968, USA
Published online on: December 5, 2012 https://doi.org/10.3892/ol.2012.1062
Pages: 663-668

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sera from patients with cancer contain antibodies which react with a unique group of autologous cellular antigens called tumor‑associated antigens (TAAs). This study aimed to determine whether a mini‑array of multiple TAAs would enhance antibody detection and be a useful approach in breast cancer detection and diagnosis. The mini‑array of multiple TAAs was composed of ten TAAs, including Imp1, p62, Koc, p53, c‑myc, survivin, p16, cyclin B1, cyclin D1 and CDK2 full‑length recombinant proteins. An enzyme‑linked immunosorbent assay (ELISA) was used to detect antibodies against these ten TAAs in 41 sera from patients with breast cancer, as well as 82 sera from normal individuals. The antibody frequency of the individual TAAs in breast cancer was variable and ranged between 7.3 and 22.0%. With the successive addition of TAAs to a final total of ten antigens, there was a stepwise increase in positive antibody reactions, reaching a sensitivity of 61.0% and a specificity of 86.6% in breast cancer. The positive and negative likelihood ratios were 5.545 and 0.438, respectively, which showed that the clinical diagnostic value of a parallel assay of eight TAAs was high. The positive and negative predictive values were 73.5 and 82.0%, respectively, indicating that the parallel assay of eight TAAs raised the diagnostic precision significantly. The agreement rate and κ-value were 79.7% and 0.52, respectively, while the Youden's Index (YI) was 0.5, indicating that the observed value of this assay had a middle range coincidence with the actual value. The data from the present study further support our previous hypothesis that the detection of autoantibodies for the diagnosis of certain types of cancer may be enhanced using a mini‑array of several TAAs as target antigens. A customized antigen mini‑array using a panel of appropriately selected TAAs is able to enhance autoantibody detection in the immunodiagnosis of breast cancer.

View Figures

View References

1.	Shin HR, Joubert C, Boniol M, et al: Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Cancer Causes Control. 21:1777–1785. 2010. View Article : Google Scholar : PubMed/NCBI
2.	American Cancer Society: Cancer Facts & Figures 2007. ACS Publication; Atlanta GA: 2007
3.	Tan EM and Zhang J: Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev. 222:328–340. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Zhang JY and Tan EM: Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn. 10:321–328. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Soussi T: p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60:1777–1788. 2000.PubMed/NCBI
6.	Looi K, Megliorino R, Shi FD, Peng XX, Chen Y and Zhang JY: Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep. 16:1105–1110. 2006.PubMed/NCBI
7.	Yamamoto A, Shimizu E, Takeuchi E, et al: Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology. 56:129–133. 1999. View Article : Google Scholar : PubMed/NCBI
8.	Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S and Cheever MA: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol. 15:3363–3367. 1997.PubMed/NCBI
9.	Zhang JY, Chan EK, Peng XX and Tan EM: A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med. 189:1101–1110. 1999. View Article : Google Scholar : PubMed/NCBI
10.	Doyle GA, Bourdeau-Heller JM, Coulthard S, Meisner LF and Ross J: Amplification in human breast cancer of a gene encoding a c-myc mRNA-binding protein. Cancer Res. 60:2756–2759. 2000.PubMed/NCBI
11.	Soo Hoo L, Zhang JY and Chan EK: Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer. Oncogene. 21:5006–5015. 2002.
12.	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
13.	Megliorino R, Shi FD, Peng XX, et al: Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev. 29:241–248. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Daniels T, Zhang J, Gutierrez I, et al: Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate. 62:14–26. 2005. View Article : Google Scholar
15.	Crawford LV, Pim DC and Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 30:403–408. 1982. View Article : Google Scholar : PubMed/NCBI
16.	Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 52:4168–4174. 1992.PubMed/NCBI
17.	Anderson KS and LaBaer J: The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 4:1123–1133. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK and Tan EM: Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev. 12:136–143. 2003.PubMed/NCBI
19.	Chen WQ: Assessing the validity and reliability of screening test. Epidemiology. Li LM: Publishing Company of the People’s Health; Beijing: pp. 289–292. 2004
20.	Koziol JA, Zhang JY, Casiano CA, et al: Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res. 9:5120–5126. 2003.PubMed/NCBI
21.	Zhang JY, Megliorino R, Peng XX, Tan EM, Chen Y and Chan EK: Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol. 46:107–114. 2007. View Article : Google Scholar
22.	Chen Y, Zhou Y, Qiu S, et al: Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett. 289:32–39. 2010. View Article : Google Scholar : PubMed/NCBI
23.	Liu W, Wang P, Li Z, et al: Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer. Scand J Immunol. 69:57–63. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Chen Y, Lin P, Qiu S, et al: Autoantibodies to Ca²⁺ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol. 30:1137–1144. 2007.
25.	Li L, Wang K, Dai L, Wang P, Peng XX and Zhang JY: Detection of autoantibodies to multiple tumor-associated antigens in the immunodiagnosis of ovarian cancer. Mol Med Rep. 1:589–594. 2008.PubMed/NCBI